Befotertinib

DRUG6 trials

Sponsors

Betta Pharmaceuticals Co., Ltd., Sun Yat-sen University, Fudan University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hebei Medical University Fourth Hospital

Conditions

3-year Disease-free SurvivalAdjuvant Drug TherapyEGFREGFR G719XEGFR L861QEGFR S768INSCLCNSCLC (Non-small Cell Lung Cancer)

Phase 2

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Active, not recruitingNCT05007938

Betta Pharmaceuticals Co., Ltd.Non-Small Cell Lung Cancer

Start: 2021-08-12End: 2024-12-31Target: 30Updated: 2024-08-23

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

RecruitingNCT06517953

Sun Yat-sen UniversityEGFR G719X, EGFR L861Q, EGFR S768I +1

Start: 2024-07-17End: 2027-12-24Target: 23Updated: 2024-07-25

Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC

RecruitingNCT06863506

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNSCLC (Non-small Cell Lung Cancer)

Start: 2024-10-01End: 2027-12-30Target: 78Updated: 2025-03-07

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

RecruitingNCT07181499

Betta Pharmaceuticals Co., Ltd.Adjuvant Drug Therapy, EGFR, NSCLC

Start: 2025-09-30End: 2028-12-31Target: 28Updated: 2025-09-30

ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy

Not yet recruitingNCT07410611

Hebei Medical University Fourth HospitalPatients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination

Start: 2026-02-10End: 2030-02-28Target: 84Updated: 2026-02-13

Phase 4

Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

RecruitingNCT06561620

Fudan University3-year Disease-free Survival

Start: 2024-05-01End: 2029-05-01Target: 592Updated: 2024-08-22